A real-world study found evolocumab cut fatal or nonfatal heart attack risk 20% vs ezetimibe in adults with ASCVD and prior statin use.
|Webcasts|September 27, 2020
Vero Cell Cultivation for Vaccine Production
Author(s)Eppendorf
***Live: Thursday, Oct. 22, 2020 at 10am EDT| 9am CDT| 3pm BST| 4pm CEST***Process development for anchorage-dependent cells at bench scale is crucial to establish cost-efficient workflows in larger volumes. Learn how different process parameter can be monitored and controlled in a perfusion bioprocess and the potential of using packed-bed bioreactors or a microcarrier spin filter for attachment cell-based vaccine production.. *** On demand available after final airing until Oct. 22, 2021.***
Register free:
Event Overview:
Anchorage-dependent cells such as vero cells are widely used as a platform for viral vector production. To cultivate vero cells in stirred-tank bioreactors, a growth matrix for the cells to attach to is required. The development of processes at bench scale is crucial to establish cost-efficient workflows in larger volumes.
In this webinar, an expert will demonstrate how different process parameter can be monitored and controlled in a perfusion bioprocess to cultivate anchorage-dependent cells. The presentation will demonstrate the potential of using packed-bed bioreactors or a microcarrier spin filter for attachment cell-based vaccine production.
Key Learning Objectives:
- Understand the importance of high-quality pre-cultures for bioreactor inoculation
- Review the importance of process monitoring and control
- Gain expertise on how to cultivate and grow anchorage dependent cells on different attachment matrices.
Speaker: Michelet Dorceus, Bioprocess Field Application Manager, Eppendorf North America
Time and Date: Thursday, October 22, 2020 at 10am EDT| 9am CDT| 3pm BST| 4pm CEST
On demand available after final airing until Oct. 22, 2021
Sponsor: Eppendorf
Register free:
Related to this article
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Johnson & Johnson's amivantamab (Rybrevant Faspro) won accelerated FDA approval for pretreated recurrent head and neck cancer.
Oxford spinout Alethio Therapeutics closed a $90 million Series A to take ATX-011, a monoclonal antibody against the G6B receptor, into Phase 1/2a studies in essential thrombocythemia. It is also developing a G6B-targeted ADC for myelofibrosis.
T-Therapeutics closed an oversubscribed $133 million Series B backed by Eli Lilly, JJDC, and others. The funding will take its first T-cell receptor bispecifics in cancer and autoimmune disease into clinical trials.
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
FDA’s draft framework would let sponsors add patient-specific genome editing variants to an approved BLA using in vitro data. Here is what the guidance proposes, what evidence it asks for, and what remains unresolved.
Healthy-volunteer data show sustained TL1A suppression and a profile supporting infrequent subcutaneous dosing. Caldera also licensed a second bispecific, targeting IL-17 and TL1A, from Qyuns Therapeutics.
Trending on BioPharm International
1
T-Therapeutics Raises $133 Million to Take TCR Bispecifics Into the Clinic
2
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
3
Boehringer Ingelheim Licenses Six Preclinical ADC and T-Cell Engager Programs From SBP Group in Deal Worth Up to $7 Billion
4
China Grants Ivonescimab Priority Review in Biliary Tract Cancer
5